|Day Low/High||10.14 / 10.77|
|52 Wk Low/High||5.21 / 22.20|
New drugs give small-cap companies opportunity to expand markets and revenues.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.
Collaboration Will Advance Highly Targeted, Patient-Specific Treatment Approach
A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday.
These stocks look ready to break out and trade higher from current levels.
First clinical data with AXAL to show evidence of cytotoxic T cell infiltration into the tumor immune microenvironment or TME for HPV-Positive oropharyngeal cancer